Dr. Sayed A. Tabatabai, M.D.
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Medical school
- Albany Medical College of Union University (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 870
Licensed in Texas since 2015, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: Albany Medical College of Union University
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
TX license Q4310 (first issued 2015; active) · NY license 264726-1
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Medical Center San Antonio, TX
- Methodist Hospital Stone Oak San Antonio, TX
- Huntsville Memorial Hospital Huntsville, TX
Medical groups
- San Antonio Kidney Disease Center Physicians Group, P.l.l.c. (33 clinicians)
- Pulse Physician Organization PLLC (17 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 870
- Services billed
- 3,104
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 690 | 409 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 431 | 190 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 382 | 48 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 347 | 134 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 208 | 198 |
| New patient office or other outpatient visit, 45-59 minutes | 82 | 82 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 39 | 21 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 33 | 31 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Losartan Potassium Other prescribers in San Antonio, TX | 133 |
| Calcitriol Other prescribers in San Antonio, TX | 90 |
| Amlodipine Besylate Other prescribers in San Antonio, TX | 88 |
| Furosemide Other prescribers in San Antonio, TX | 84 |
| Carvedilol Other prescribers in San Antonio, TX | 79 |
| Nifedipine Er (nifedipine) Other prescribers in San Antonio, TX | 73 |
| Cephalexin Other prescribers in San Antonio, TX | 60 |
| Farxiga (dapagliflozin propanediol) Other prescribers in San Antonio, TX | 60 |
| Potassium Chloride Other prescribers in San Antonio, TX | 59 |
| Allopurinol Other prescribers in San Antonio, TX | 57 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 40 payments worth $1,251 in total to this clinician.
| Inspire Medical Systems, Inc. | $295 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $266 |
| Otsuka America Pharmaceutical, Inc. | $99.29 |
| Calliditas Therapeutics US Inc. | $79.40 |
| Amgen Inc. | $73.81 |
| Travere Therapeutics, Inc. | $70.40 |
| Novartis Pharmaceuticals Corporation | $61.04 |
| Ardelyx, Inc. | $51.19 |
| Food and Beverage | $1,251 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $108,869 in research payments for these studies, mostly to the institutions running them.
- Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Csl Behring · Recruiting · NCT05485961 - A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis
Akebia Therapeutics Inc
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.